Session » (0199–0209) Infection-related Rheumatic Disease Poster

Date: Sunday, October 26, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 0209

A Retrospective Safety Analysis based on Platelets in Arthrocentesis and Joint injections in Cancer Patients

10:30AM-12:30PM: Abstract Number: 0208

Current practices and challenges in tuberculosis screening and preventive treatment among patients with rheumatic diseases: A multiregional physician survey in China

10:30AM-12:30PM: Abstract Number: 0204

Immunogenicity and safety summary for the chikungunya virus-like particle vaccine development programme

10:30AM-12:30PM: Abstract Number: 0205

Implementation of the Varicella Zoster virus vaccine and its Real-World effectiveness

10:30AM-12:30PM: Abstract Number: 0199

Pain Phenotypes and Social Determinants of Health in Chronic Chikungunya Arthritis: A Cross-Sectional Study

10:30AM-12:30PM: Abstract Number: 0206

Prospective Controlled Study of Humoral Response to Recombinant Zoster Vaccine in Cyclophosphamide-Treated Autoimmune Rheumatic Disease Patients: No Additional Impairment Compared to Other Immunosuppressive Therapies

10:30AM-12:30PM: Abstract Number: 0201

Real-World study of immunogenicity and safety of the adjuvant recombinant vaccine against varicella zoster virus in patients with immune-mediated inflammatory diseases treated with Janus Kinase Inhibitors in comparison with healthy individuals

10:30AM-12:30PM: Abstract Number: 0203

Risk Factors for Cytomegalovirus Infection in Patients Receiving Prolonged High-Dose Corticosteroids for Rheumatic Diseases: A Retrospective Cohort Study

10:30AM-12:30PM: Abstract Number: 0202

Saudi Society for Rheumatology Consensus Recommendation on Vaccination Strategies in Adults Saudi with Autoimmune Rheumatic Disorders

10:30AM-12:30PM: Abstract Number: 0200

Severe infections and malignancies in patients with cranial and extracranial giant cell arteritis treated with tocilizumab. National multicenter study of 471 patients of clinical practice

10:30AM-12:30PM: Abstract Number: 0207

The Feasibility and Clinical Effects of Anti-Inflammatory Diet Intervention In Patients Diagnosed With Long COVID (Post-Acute Sequelae of SARS CoV-2, PASC)

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].